12:00 AM
 | 
Jun 17, 2002
 |  BioCentury  |  Product Development

CD40 deja vu

CD40 ligand is a logical target for certain autoimmune diseases and cancers, as it is primarily expressed on CD4 T cells and enhances the co-stimulatory function of antigen presenting cells, including dendritic cells, B cells and monocytes. However, when Idec Pharmaceutical Corp. last week halted all Phase II trials of its IDEC-131 antibody against CD40L due to a thromboembolic event, the news corroborated growing evidence that the ligand poses a cardiovascular risk and edges the compound nearer to a growing mound of Phase II CD40 and CD40L cast-offs.

CD40L is a member of the

Read the full 451 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >